TissueGen solves for unmet needs through the development of transformative drug delivery technologies that reduce treatment burden and improve clinical outcomes. We create life changing treatment modalities for patients and their caregivers, treating both acute and chronic conditions.
Looking for a particular TissueGen, Inc. employee's phone or email?
The TissueGen, Inc. annual revenue was $9 million in 2026.
Kevin Nelson is the Chief Scientific Officer of TissueGen, Inc..
7 people are employed at TissueGen, Inc..
TissueGen, Inc. is based in Dallas, Texas.
The NAICS codes for TissueGen, Inc. are [32541, 325, 32, 3254].
The SIC codes for TissueGen, Inc. are [283, 28].